News
![Waters Peptide Multi-Attribute Method for BioAccord System Boosts Innovator and Biosimilar Drug Development and Commercialization](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Waters Peptide Multi-Attribute Method for BioAccord System Boosts Innovator and Biosimilar Drug Development and Commercialization
Waters Corporation (NYSE:WAT) today introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC
![Agilent Announces Cash Dividend of 19.4 Cents per Share](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Agilent Announces Cash Dividend of 19.4 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced that a quarterly dividend of 19.4 cents per share of common stock will be paid on April 28, 2021, to all shareholders of record as of the close
![Der erste Patient schließt in Phase IIb die digitale Einwilligung mit dem Veeva Clinical Network ab](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Der erste Patient schließt in Phase IIb die digitale Einwilligung mit dem Veeva Clinical Network ab
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass Veeva eConsent, eine MyVeeva for Patients-Anwendung, die auf dem Veeva Clinical Network basiert, von seinem ersten Patienten eine elektronische
EUROIMMUN bringt ultraschnelles automatisiertes Mikroskop und intelligente Software für moderne Befunderhebung am Bildschirm auf den Markt
EUROIMMUN, a PerkinElmer, Inc. company, gab heute die Markteinführung des kompakten Immunfluoreszenz-Mikroskops EUROPattern Microscope Live (EPML) mit EUROLabOffice 4.0 (ELO 4.0), der vierten
![Humana Introduces CenterWell as the New Brand for a Range of Its Payer-Agnostic Health Care Services Offerings](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana Introduces CenterWell as the New Brand for a Range of Its Payer-Agnostic Health Care Services Offerings
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today a new brand – CenterWell – to describe and connect a range of the company’s payer-agnostic health care services
![First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study
Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early
![First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study
Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early
![Agilent Announces the 8697 Headspace Sampler with Integrated Intelligence](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Agilent Announces the 8697 Headspace Sampler with Integrated Intelligence
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent 8697 Headspace Sampler, the first headspace sampler with integrated gas chromatography communication. It marks the expansion of
![Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women
Illumina, Inc. (NASDAQ: ILMN), along with researchers at the University of Colorado and Harvard Pilgrim Health Care (HPHC), reported study results evaluating the impact of an innovative
![Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declaredhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
The Israel Ministry of Health (MoH), Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease
![Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector
Waters Corporation (NYSE:WAT) today released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight (TOF) mass spectrometer (MS) for small molecule analysis for
![Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer
Agilent Technologies Inc. (NYSE: A), today announced that Dr. Katharine (Kate) Knobil is joining Agilent as the company’s chief medical officer (CMO). The chief medical officer at Agilent is a
PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations
PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX®
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec
![Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection
Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in
![Neue Studie zeigt auf, dass mehr Auftragsforschungsinstitute Maßnahmen ergreifen, um dem dringenden Bedarf an schnelleren klinischen Studien gerecht zu werden](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Neue Studie zeigt auf, dass mehr Auftragsforschungsinstitute Maßnahmen ergreifen, um dem dringenden Bedarf an schnelleren klinischen Studien gerecht zu werden
Auftragsforschungsinstitute machen bedeutende Fortschritte bei der Modernisierung und Verkürzung klinischer Studien, so die Ergebnisse der aktuellen Veeva Unified Clinical Operations Survey: Annual
![Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
Illumina, Inc.’s (NASDAQ: ILMN) NextSeq™ 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq™Dx which was approved previously
PerkinElmer Prices Offering of Senior Notes
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $400.0 million aggregate principal amount of 2.550%
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, Executive Vice President, Global Supply, at the
![New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials
Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to the latest Veeva Unified Clinical Operations Survey: Annual CRO
![New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials
Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to the latest Veeva Unified Clinical Operations Survey: Annual CRO
![U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA® (lorlatinib), expanding the indication to include first-line
![Agilent Technologies Announces Pricing of $850 Million of Senior Notes](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Technologies Announces Pricing of $850 Million of Senior Notes
Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $850 million. The
![Humana and the University of Houston Announce New Value-based Care Specialization Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=us)
Humana and the University of Houston Announce New Value-based Care Specialization Program
Today, Humana (NYSE: HUM) and the University of Houston announced the launch of a Value-based Care Specialization online program to support providers, academia and other business and industry
![Agilent Technologies Announces Proposed Offering of Senior Notes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Agilent Technologies Announces Proposed Offering of Senior Notes
Agilent Technologies Inc. (NYSE:A) today announced it is offering, subject to market and other conditions, a series of senior notes under an automatic shelf registration statement on file with the